WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens

References

• Sugiyama H. Wilms’ tumor gene WT1: its oncogenic function and clinical application. Int J Hematol. 2001;73(2):177–187. doi:10.1007/BF02981935
   PubMed Web of Science ®Google Scholar
• Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood. 1994;84(9):3071–3079. doi:10.1182/blood.V84.9.3071.3071
   PubMed Web of Science ®Google Scholar
• Inoue K, Ogawa H, Sonoda Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood. 1997;89(4):1405–1412. doi:10.1182/blood.V89.4.1405
   PubMed Web of Science ®Google Scholar
• Trka J, Kalinova M, Hrusak O, et al. Real-time quantitative PCR detection of WT1 gene expression in children with AML: prognostic significance, correlation with disease status and residual disease detection by flow cytometry. Leukemia. 2002;16(7):1381–1389. doi:10.1038/sj.leu.2402512
   PubMed Web of Science ®Google Scholar
• Garg M, Moore H, Tobal K, et al. Prognostic significance of quantitative analysis of WT1 gene transcripts by competitive reverse transcription polymerase chain reaction in acute leukaemia. Br J Haematol. 2003;123(1):49–59. doi:10.1046/j.1365-2141.2003.04552.x
   PubMed Web of Science ®Google Scholar
• Lapillonne H, Renneville A, Auvrignon A, et al. High WT1 expression after induction therapy predicts high risk of relapse and death in pediatric acute myeloid leukemia. J Clin Oncol. 2006;24(10):1507–1515. doi:10.1200/JCO.2005.03.5303
   PubMed Web of Science ®Google Scholar
• Cilloni D, Messa F, Arruga F, et al. Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy. Haematologica. 2008;93(6):921–924. doi:10.3324/haematol.12165
   PubMed Web of Science ®Google Scholar
• Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms’ tumor locus. Cell. 1990;60(3):509–520. doi:10.1016/0092-8674(90)90601-a
   PubMed Web of Science ®Google Scholar
• Yang L, Han Y, Suarez SF, et al. A tumor suppressor and oncogene: the WT1 story. Leukemia. 2007;21(5):868–876. doi:10.1038/sj.leu.2404624
   PubMed Web of Science ®Google Scholar
• Yamagami T, Sugiyama H, Inoue K, et al. Growth inhibition of human leukemic cells by WT1 (Wilms tumor gene) antisense oligodeoxynucleotides: implications for the involvement of WT1 in leukemogenesis. Blood. 1996;87(7):2878–2884. doi:10.1182/blood.V87.7.2878.bloodjournal8772878
   PubMed Web of Science ®Google Scholar
• Nishida S, Hosen N, Shirakata T, et al. AML1-ETO rapidly induces acute myeloblastic leukemia in cooperation with the Wilms tumor gene, WT1. Blood. 2006;107(8):3303–3312. doi:10.1182/blood-2005-04-1656
   PubMed Web of Science ®Google Scholar
• Ariyaratana S, Loeb DM. The role of the Wilms tumour gene (WT1) in normal and malignant haematopoiesis. Expert Rev Mol Med. 2007;9(14):1–17. doi:10.1017/S1462399407000336
   PubMedGoogle Scholar
• King-Underwood L, Renshaw J, Pritchard-Jones K. Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood. 1996;87(6):2171–2179.
   PubMed Web of Science ®Google Scholar
• Hou HA, Huang TC, Lin LI, et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood. 2010;115(25):5222–5231. doi:10.1182/blood-2009-12-259390
   PubMed Web of Science ®Google Scholar
• Virappane P, Gale R, Hills R, et al. Mutation of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemotherapy resistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol. 2008;26(33):5429–5435. doi:10.1200/JCO.2008.16.0333
   PubMed Web of Science ®Google Scholar
• Gaidzik VI, Schlenk RF, Moschny S, et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood. 2009;113(19):4505–4511. doi:10.1182/blood-2008-10-183392
   PubMed Web of Science ®Google Scholar
• Paschka P, Marcucci G, Ruppert AS, et al. Wilms tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a cancer and leukemia group B study. J Clin Oncol. 2008;26(28):4595–4602. doi:10.1200/JCO.2007.15.2058
   PubMed Web of Science ®Google Scholar
• Renneville A, Boissel N, Zurawski V, et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer. 2009;115(16):3719–3727. doi:10.1002/cncr.24442
   PubMed Web of Science ®Google Scholar
• Wood BL. Acute myeloid leukemia minimal residual ­disease detection: the difference from normal approach. Curr Protoc Cytom. 2020; 93(1):e73. doi:10.1002/cpcy.73
   PubMedGoogle Scholar
• Lee SI, Celik S, Logsdon BA, et al. A machine learning approach to integrate big data for precision medicine in acute myeloid leukemia. Nat Commun. 2018; 9(1):42. PMID: 29298978; PMCID: PMC5752671. doi:10.1038/s41467-017-02465-5
   PubMedGoogle Scholar
• Kongtim P, Percival ME, Martins TJ, et al. Long-term outcomes of a clinical trial of molecular and functional drug screening for individualized therapy in relapsed and refractory (R/R) acute leukemia (AL). Blood. 2022;140(Suppl 1):1200–1202. doi:10.1182/blood-2022-165801
   PubMedGoogle Scholar
• Burnett AK, Russell NH, Hills RK, et al. Optimization of chemotherapy for younger patients with. acute myeloid leukemia: results of the medical research council AML15 trial. J Clin Oncol. 2013;31(27):3360–3368. doi:10.1200/JCO.2012.47.4874
   PubMed Web of Science ®Google Scholar
• Atluri H, Patel KP, Routbort MJ, et al. European Hematology Association, (Abstract release date: 05/11/23), EHA Library. Atluri H. 06/08/2023; 386412; P583 2023.
   Google Scholar
• Malani D, Kumar A, Brück O, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022; 12(2):388–401. PMID: 34789538; PMCID: PMC9762335. doi:10.1158/2159-8290.CD-21-0410
   PubMed Web of Science ®Google Scholar